AmerisourceBergen Drug Corporation
AmerisourceBergen Drug Corporation, commonly referred to as AmerisourceBergen, is a leading global healthcare solutions provider headquartered in the United States. Founded in 2001, the company has established itself as a key player in the pharmaceutical distribution industry, serving healthcare providers across North America and beyond. Specialising in pharmaceutical distribution, AmerisourceBergen offers a comprehensive range of services, including supply chain management, logistics, and consulting. The company is renowned for its commitment to improving patient access to medications and enhancing the efficiency of healthcare delivery. With a strong market position, AmerisourceBergen has achieved significant milestones, including strategic partnerships and innovative solutions that set it apart in the competitive landscape.
DitchCarbon Score
How does AmerisourceBergen Drug Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AmerisourceBergen Drug Corporation's score of 16 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
AmerisourceBergen Drug Corporation's reported carbon emissions
In 2021, AmerisourceBergen Drug Corporation reported significant carbon emissions, totalling approximately 112,936,750 kg CO2e for Scope 1 and 96,472,630 kg CO2e for Scope 2 on a global scale. The company also disclosed Scope 3 emissions, which included approximately 21,151,776,940 kg CO2e from purchased goods and services, 741,348,030 kg CO2e from downstream transportation and distribution, and 32,800,4430 kg CO2e from upstream transportation and distribution. In 2020, the corporation's emissions were slightly lower, with Scope 1 emissions at about 108,025,000 kg CO2e and Scope 2 emissions at approximately 99,197,250 kg CO2e. The trend indicates a focus on monitoring and reporting emissions, although specific reduction targets or initiatives have not been disclosed. AmerisourceBergen has not established formal reduction targets or climate pledges as per the available data. The company continues to engage in climate-related reporting, reflecting an awareness of its environmental impact and a commitment to transparency in emissions data.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Scope 1 | 109,727,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 105,581,090 | 00,000,000 | 00,000,000 |
| Scope 3 | 19,532,581,490 | - | 00,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
AmerisourceBergen Drug Corporation is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
